A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
about
Trial watch - inhibiting PARP enzymes for anticancer therapyEffectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysisBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingTargeting DNA damage response in cancer therapyTherapeutic targeting of cancers with loss of PTEN function.Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibitionA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursSynthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsThe PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient micePhase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibitionDevelopment of synthetic lethality anticancer therapeutics.An update on PARP inhibitors for the treatment of cancerNovel and emerging targeted-based cancer therapy agents and methods.YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent CellsPhase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerStrategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced CytotoxicityPARP Inhibitors in Reproductive System Cancers: Current Use and Developments.PARP inhibitors: polypharmacology versus selective inhibition.Predictive biomarkers for cancer therapy with PARP inhibitors.PARP inhibitors for anticancer therapy.What is the role of chemotherapy in the treatment of melanoma?Deciphering the insights of poly(ADP-ribosylation) in tumor progression.Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells.Drug Monographs: Olaratumab and Rucaparib.A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.PARP inhibitors as antitumor agents: a patent update (2013-2015).AMPK in Pathogens.Rucaparib: First Global Approval.Four-component strategy for selective synthesis of azepino[5,4,3-cd]indoles and pyrazolo[3,4-b]pyridinesPARP inhibitors: current status and implications for anticancer therapeutics.
P2860
Q26745673-E784B2DD-B82C-4885-9DCC-6E7F9D2CA198Q26781792-F5B421B4-CF8A-4241-A38A-F7D67BE3DA4DQ26852274-03747427-0160-45FC-8223-926D89C0A3FBQ26863501-37EBEFE8-4E8E-4021-8A72-923505DC6ED1Q27023204-1D121363-EF37-43D8-AA72-53EA32D95AA7Q27852764-76332E9B-4FDB-4133-81B2-A28A4C3BA64DQ29030215-336A05B5-6DA7-4204-AF8A-B6187E942834Q33439527-9C29C0A1-D828-43A2-89C6-AD5D46016F89Q33607384-5BA10762-BBFB-48C0-BB14-8316D7A60EB4Q33617922-9B23367E-BA9F-4F77-AA21-A9D696195D46Q33618910-81F0F80C-C288-4E3C-9AF1-D49CD75879D8Q33874466-37740D93-EC6C-44C4-AFC7-FDC054C0D914Q33954553-ED53A935-AF6B-4541-8783-9978EBC9B7EEQ34034221-960D5FA8-6234-4DBA-A991-1BC3CC6D29E5Q34380368-DE6669A0-1DD2-4965-B3F8-67F38C7075E8Q35142718-36B45214-07DA-41E6-85DE-68A45090B294Q35558057-F278A2DA-196B-4C06-9A64-0A024643D7B1Q35676066-42BB1E23-5E1C-4CD7-BFC5-8F41B1BFB993Q35799917-A3CD9DE8-4C6C-4BAF-8034-7DE0F5630B4EQ36102008-543DEC62-F040-4418-A9A1-C7DE36646D5CQ36104739-E3CAAB51-4309-4CC4-8576-50CB09EDF9FAQ36257738-3FEBEB17-75D9-4601-9FB0-3F8D3D76FD9CQ36562360-0A716A97-A32F-4138-BC72-141A66FD56CFQ36767034-BC929136-BD8A-468D-8F20-9B1B37C2F070Q36941966-4C0FC9D1-CCB7-403F-9A7C-186EB7064FC9Q37205681-12BDC4E6-0D2F-43CA-9005-0C9E0448A004Q37607283-64EF55F8-3770-474C-B945-4AFED4248C76Q38100299-D980BEE3-2DCD-41A2-9F5F-1BCD32B82A79Q38137764-DB5196F0-6C42-4E3E-AB7D-9D6AC5A045B2Q38180762-570EB9B1-FCD8-41B5-B849-E02A2C18CD12Q38193716-5EED507B-0A81-42D7-8AD6-AE94695344E8Q38325685-F5428BAD-FF59-4F87-B0B3-B549AB4304D9Q38747870-F7D6F4C6-A764-4968-A2F5-759722DC73DFQ38779989-5D78E29E-335D-4F22-BB7E-048E0A0FBD82Q38780396-1DFEF856-1952-40DE-9DBE-E666C523EC6EQ38795712-777828AC-9576-45FD-818F-6EFE62A188CBQ38998422-3836E7E3-8C6E-42B1-A800-BD9EBD55B046Q39155735-C4C5585F-8C4E-45D1-BF57-3CA49231442BQ40787385-26A7E73A-4649-4923-A193-6B86CDF5EAACQ42107579-C33895C3-7ACB-4650-920E-EB500643CE2B
P2860
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
description
article
@en
im Februar 2013 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2013
@uk
name
A phase II study of the potent ...... evidence of chemopotentiation
@en
A phase II study of the potent ...... evidence of chemopotentiation
@nl
type
label
A phase II study of the potent ...... evidence of chemopotentiation
@en
A phase II study of the potent ...... evidence of chemopotentiation
@nl
prefLabel
A phase II study of the potent ...... evidence of chemopotentiation
@en
A phase II study of the potent ...... evidence of chemopotentiation
@nl
P2093
P2860
P1476
A phase II study of the potent ...... evidence of chemopotentiation
@en
P2093
Antonello Abbattista
Diane Wang
Evan Mulligan
Hilary Calvert
Jorge Gallo
Lucy Scott
Mark R Middleton
Neil Steven
Richard H Wilson
P2860
P2888
P304
P356
10.1007/S00280-013-2113-1
P577
2013-02-20T00:00:00Z